Get started
BIOGEN DRNBIOGEN DRNBIOGEN DRN

BIOGEN DRN

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals Bonds

BIIB34 chart


Full chart

Key facts today


Goldman Sachs has revised Biogen's price target to $219 from $245 while keeping a 'Buy' rating on the stock.
Biogen has filed a request to dismiss a class action lawsuit initiated by investors, with a Massachusetts court set to determine the case's progression.
Analyze the impactAnalyze the impact

Key stats


Market capitalization
‪99.11 B‬ BRL
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
11,118.18
Basic EPS (TTM)
0.01 BRL
Net income (FY)
‪8.80 B‬ BRL
Revenue (FY)
‪49.96 B‬ BRL
Shares float
—
Beta (1Y)
−0.16

About Biogen Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Christopher A. Viehbacher
Website
biogen.com
Headquarters
Cambridge
Founded
1978
ISIN
BRBIIBBDR001
FIGI
BBG00CRJ2VY4
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

BIIB34 news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

BIIB34 highest yielding bonds


BIIB4981508
Biogen Inc. 3.15% 01-MAY-2050
Yield to maturity
7.93%
Maturity date
May 1, 2050
BIIB5133378
Biogen Inc. 3.25% 15-FEB-2051
Yield to maturity
7.74%
Maturity date
Feb 15, 2051
US9062XAD5
BIOGEN INC. 15/45
Yield to maturity
6.83%
Maturity date
Sep 15, 2045
BIIB4981506
Biogen Inc. 2.25% 01-MAY-2030
Yield to maturity
5.55%
Maturity date
May 1, 2030
IDPC
BIOGEN INC. 15/25
Yield to maturity
5.32%
Maturity date
Sep 15, 2025
BIIB5133379
Biogen Inc. 3.25% 15-FEB-2051
Yield to maturity
4.65%
Maturity date
Feb 15, 2051

See all BIIB34 bonds 

Sparks


Curated watchlists where BIIB34 is featured.

See all sparks 


Check out other big names from the same industry as BIIB34.